BI Asset Management Fondsmaeglerselskab’s Catalyst Pharmaceutical CPRX Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.2M	Buy	+133,471	New	+$3.94M	0.03%	307
2025 Q3	–	Sell	-9,847	Closed	-$214K	–	722
2025 Q2	$214K	Sell	9,847 -4,401	-31%	-$104K	﹤0.01%	622
2025 Q1	$346K	Sell	14,248 -102,510	-88%	-$2.31M	﹤0.01%	602
2024 Q4	$2.44M	Buy	+116,758	New	+$2.51M	0.03%	314

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

GCM

Gables Capital Management Miami, Florida $277M AUM 41.87% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's CPRX Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 133,471 shares worth $4.2M. The stake represents 0.03% of the portfolio and ranks #307 among its holdings. This is a return to the name: BI Asset Management Fondsmaeglerselskab previously reported a position in CPRX as recently as Q2 2025.

BI Asset Management Fondsmaeglerselskab first reported a position in CPRX in Q4 2024 and has held it in 4 quarters since. 182 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 133,471 shares of Catalyst Pharmaceutical worth $4.2M as of Q2 2026.
Catalyst Pharmaceutical was a new BI Asset Management Fondsmaeglerselskab position in Q2 2026.
Catalyst Pharmaceutical made up 0.03% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #307 holding.
BI Asset Management Fondsmaeglerselskab first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 4 quarters since.
182 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.